复方丹参滴丸联合西药治疗老年冠心病合并慢性心力衰竭临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541;R256.2

基金项目:


Clinical Study on Compound Danshen Dripping Pills Combined with Western Medicine for Senile Patients with Coronary Heart Disease Complicated with Chronic Heart Failure
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察复方丹参滴丸联合西药治疗老年冠心病合并慢性心力衰竭的临床疗效。方法:采用随 机数字表法将2020年3月—2023年5月杭州市西湖区蒋村街道社区卫生服务中心收治的116例老年冠心病合并 慢性心力衰竭患者分为试验组和对照组各58例。对照组给予西药治疗,试验组在对照组基础上联合复方丹参 滴丸治疗。2组均连续治疗6个疗程。比较2组治疗前后美国纽约心脏病协会(NYHA) 心功能分级、心功能指 标[左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)] 及血清脂蛋白相 关磷脂酶A2(LP-PLA2)、心型脂肪酸结合蛋白(hFABP)、可溶性生长刺激表达基因2蛋白(sST2) 的水平, 并评估2组临床疗效及不良反应发生情况。结果:治疗后,试验组总有效率94.83% (55/58),高于对照组 79.31% (46/58)(P<0.05)。治疗后,2组NYHA心功能分级较治疗前减轻(P<0.05),且试验组NYHA心功 能分级轻于对照组(P<0.05)。治疗后,2组中医证候积分及LVEDD、LVESD、hFABP、LP-PLA2、sST2水平 均较治疗前降低(P<0.05),LVEF水平升高(P<0.05),且试验组中医证候积分及LVEDD、LVESD、hFABP、 LP-PLA2、sST2 水平低于对照组(P<0.05),LVEF 水平高于对照组(P<0.05)。试验组不良反应发生率 1.72% (1/58),低于对照组12.07% (7/58)(P<0.05)。结论:复方丹参滴丸联合西药治疗老年冠心病合并慢 性心力衰竭疗效确切,能有效增强患者心功能,降低心肌炎性损伤,安全性较高。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Compound Danshen Dripping Pills combined with western medicine on senile patients with coronary heart disease complicated with chronic heart failure. Methods: A total of 116 cases of senile patients with coronary heart disease complicated with chronic heart failure treated at Jiangcun Community Health Service Center,Xihu District,Hangzhou City from March 2020 to May 2023 were divided into the trial group and the control group according to the random number table method,with 58 cases in each group. The control group was treated with western medicine,and the trial group was additionally treated with Compound Danshen Dripping Pills based on the treatment of the control group. Both groups were treated for six consecutive courses.The traditional Chinese medicine (TCM) syndromes scores,New York Heart Association (NYHA) cardiac function grading,and the levels of heart function indexes [left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter( LVESD),left ventricular ejection fraction( LVEF)],lipoprotein-associated phospholipase A2( LP-PLA2), heart-type fatty acid-binding protein (hFABP),and soluble growth stimulation expressed gene 2 protein (sST2) in the two groups were compared before and after treatment. Clinical effects and adverse reactions in the two groups were evaluated. Results:After treatment,the total effective rate was 94.83%( 55/58) in the trial group,higher than that of 79.31% (46/58) in the control group (P<0.05). The NYHA cardiac function grading in the two groups after treatment was milder than that before treatment (P<0.05), and the NYHA cardiac function grading in the trial group was relieved compared to the control group (P<0.05). After treatment,TCM syndrome scores and the levels of LVEDD, LVESD, hFABP, LP-PLA2, and sST2 in the two groups were decreased when compared with those before treatment( P<0.05),and LVEF levels were increased( P<0.05);the TCM syndrome score and the levels of LVEDD, LVESD,hFABP,LP-PLA2,and sST2 in the trial group were lower than those in the control group (P<0.05),and the LVEF level was higher than that in the control group (P<0.05). The incidence of adverse reactions was 1.72% (1/ 58) in the trial group, lower than that of 12.07% (7/58) in the control group (P<0.05). Conclusion: Compound Danshen Dripping Pills combined with western medicine has a definite curative effect in treating senile patients with coronary heart disease complicated with chronic heart failure,which can significantly enhance their heart function and reduce myocardial inflammatory injury,with high safety.

    参考文献
    相似文献
    引证文献
引用本文

顾玲丽,钱建明,毛桂红,周方.复方丹参滴丸联合西药治疗老年冠心病合并慢性心力衰竭临床研究[J].新中医,2025,57(1):32-36

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-01-14
  • 出版日期:
文章二维码